CN107311988A - 一种治疗阿尔茨海默病的药物 - Google Patents
一种治疗阿尔茨海默病的药物 Download PDFInfo
- Publication number
- CN107311988A CN107311988A CN201710578019.8A CN201710578019A CN107311988A CN 107311988 A CN107311988 A CN 107311988A CN 201710578019 A CN201710578019 A CN 201710578019A CN 107311988 A CN107311988 A CN 107311988A
- Authority
- CN
- China
- Prior art keywords
- formula
- medicine
- alzheimer disease
- treating alzheimer
- bis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000020510 functional beverage Nutrition 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract description 10
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract description 10
- 230000004083 survival effect Effects 0.000 abstract description 10
- 239000013641 positive control Substances 0.000 abstract description 7
- 230000005779 cell damage Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000004069 differentiation Effects 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- -1 fluoro- quinazolyl Chemical group 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000010792 warming Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical class C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- CJGKNWNOOUZIDB-UHFFFAOYSA-N 2-fluoroquinazoline Chemical class C1=CC=CC2=NC(F)=NC=C21 CJGKNWNOOUZIDB-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 125000004802 cyanophenyl group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- GNUFQJQCEBFWDQ-UHFFFAOYSA-N (3,5-difluorophenoxy)boronic acid Chemical class OB(O)OC1=CC(F)=CC(F)=C1 GNUFQJQCEBFWDQ-UHFFFAOYSA-N 0.000 description 1
- CCQCRVHVJHAXJB-UHFFFAOYSA-N (4-propan-2-ylphenoxy)boronic acid Chemical compound CC(C)C1=CC=C(OB(O)O)C=C1 CCQCRVHVJHAXJB-UHFFFAOYSA-N 0.000 description 1
- 102100027831 14-3-3 protein theta Human genes 0.000 description 1
- YEUFXMPHEYKKGP-UHFFFAOYSA-N 3-bromopyrazine-2-carbaldehyde Chemical compound BrC1=NC=CN=C1C=O YEUFXMPHEYKKGP-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- ZXZBMGGWHWRHPS-UHFFFAOYSA-N cyanato(phenyl)borinic acid Chemical compound N#COB(O)C1=CC=CC=C1 ZXZBMGGWHWRHPS-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical compound P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
组别 | 细胞存活率 |
空白对照组 | 100 |
模型组 | 21 |
阳性对照组 | 74 |
Ⅰa | 99 |
Ⅰb | 76 |
Ⅰc | 88 |
Ⅰd | 99 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710578019.8A CN107311988B (zh) | 2017-07-15 | 2017-07-15 | 一种治疗阿尔茨海默病的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710578019.8A CN107311988B (zh) | 2017-07-15 | 2017-07-15 | 一种治疗阿尔茨海默病的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107311988A true CN107311988A (zh) | 2017-11-03 |
CN107311988B CN107311988B (zh) | 2018-08-21 |
Family
ID=60177918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710578019.8A Active CN107311988B (zh) | 2017-07-15 | 2017-07-15 | 一种治疗阿尔茨海默病的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107311988B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101218206A (zh) * | 2005-07-04 | 2008-07-09 | 诺沃-诺迪斯克有限公司 | 组胺h3受体拮抗剂 |
WO2008099210A2 (en) * | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
WO2009037247A1 (en) * | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
CN103328468A (zh) * | 2010-10-27 | 2013-09-25 | 普罗克斯马根有限公司 | 用于治疗疼痛、精神障碍、认知损害或阿尔茨海默病的α-7烟碱型受体调节剂 |
WO2014165263A1 (en) * | 2013-03-12 | 2014-10-09 | The Regents Of The University Of California, A California Corporation | Gamma-secretase modulators |
CN105189494A (zh) * | 2013-03-13 | 2015-12-23 | 普罗克西梅根有限公司 | 作为ssao抑制剂的咪唑并[4,5-c]吡啶和吡咯并[2,3-c]吡啶衍生物 |
-
2017
- 2017-07-15 CN CN201710578019.8A patent/CN107311988B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101218206A (zh) * | 2005-07-04 | 2008-07-09 | 诺沃-诺迪斯克有限公司 | 组胺h3受体拮抗剂 |
WO2008099210A2 (en) * | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
WO2009037247A1 (en) * | 2007-09-17 | 2009-03-26 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
CN103328468A (zh) * | 2010-10-27 | 2013-09-25 | 普罗克斯马根有限公司 | 用于治疗疼痛、精神障碍、认知损害或阿尔茨海默病的α-7烟碱型受体调节剂 |
WO2014165263A1 (en) * | 2013-03-12 | 2014-10-09 | The Regents Of The University Of California, A California Corporation | Gamma-secretase modulators |
CN105189494A (zh) * | 2013-03-13 | 2015-12-23 | 普罗克西梅根有限公司 | 作为ssao抑制剂的咪唑并[4,5-c]吡啶和吡咯并[2,3-c]吡啶衍生物 |
Also Published As
Publication number | Publication date |
---|---|
CN107311988B (zh) | 2018-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7035108B2 (ja) | プリドピジンの類似体、それらの製造および使用 | |
CN109563060B (zh) | Ido1抑制剂及其制备方法和应用 | |
CN115175679A (zh) | 治疗***受体相关疾病的方法 | |
CN103159760A (zh) | 作为cftr调控剂的氮杂吲哚衍生物 | |
CN101084205A (zh) | 作为5ht2c受体调节剂以治疗与其相关病症的n-联芳基和n-芳基杂芳基哌嗪衍生物 | |
CN107556361A (zh) | 裂环羽扇豆烷衍生物及其抗肿瘤用途 | |
CN105814039B (zh) | 氟苯基吡唑化合物 | |
CN108929329A (zh) | 2-氮杂环-5-三氟甲基-8-硝基苯并(硫代)吡喃-4-酮类化合物 | |
RU2537847C2 (ru) | Новые фумаратные соли антагониста гистаминового рецептора н3 | |
CN101781293A (zh) | 一种抗菌化合物及其制备方法和应用 | |
WO2023000398A1 (zh) | 一种石蒜碱β-芳基丙烯酸酯衍生物及其制备方法和用途 | |
CN107311988B (zh) | 一种治疗阿尔茨海默病的药物 | |
CN103360342B (zh) | 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用 | |
CN105085308B (zh) | 菖蒲酰胺类化合物及其制备方法与应用 | |
CN104116728B (zh) | 一种由异羟肟酸类化合物和维生素a酸类化合物组成的药物组合物及其应用 | |
CN116514777A (zh) | 驱动蛋白kif18a抑制剂及其应用 | |
CN107184584B (zh) | 一种治疗阿尔茨海默病的药物 | |
US9545387B2 (en) | Composition and kit comprising piperazine derivatives and metformin, and use thereof in the treatment of diabetes | |
CN110105323B (zh) | 二芳基丙烷二聚体类衍生物及其药物组合物和其应用 | |
CN104224796B (zh) | 齐墩果烷型三萜类酯衍生物抗神经退行性药物用途 | |
CN104045598B (zh) | 一种含芳胺结构的硫脲类化合物及其制备方法和应用 | |
CN111825608A (zh) | 四氢喹啉类与四氢异喹啉类化合物及其用途 | |
CN104151242A (zh) | 二氢异喹啉类化合物及其在制备神经保护或抗抑郁药物中的用途 | |
CN108159035A (zh) | 肉桂酸类衍生物的新用途 | |
CN112225733B (zh) | 一种含1,3,4-噻二唑吡啶-2-酮衍生物的制备方法和作为抗癌药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180706 Address after: No. 200, companion Kun Road, Minhang District, Shanghai Applicant after: Shanghai Pukang Pharmaceutical Co.,Ltd. Address before: 262600 Wolong Town, Linqu County, Weifang, Shandong Applicant before: Ju De Feng |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A drug for treating Alzheimer's disease Effective date of registration: 20230627 Granted publication date: 20180821 Pledgee: Bank of Hangzhou Limited by Share Ltd. Shanghai branch Pledgor: Shanghai Pukang Pharmaceutical Co.,Ltd. Registration number: Y2023310000315 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |